3 Global IT Services Company, Specialty Pharmaceuticals Company and Multi Speciality Hospital Chain Stocks With a Strong Future Roadmap: Mphasis, Ajanta Pharma and Global Health

IT services, pharma and hospital stocks offer a focused view of a sector where demand keeps widening. Mphasis, Ajanta Pharma and Global Health cover a global IT services company, a specialty pharmaceuticals company and a multi speciality hospital chain.

This list covers three IT services, pharma and hospital stocks with complete current figures: Mphasis, Ajanta Pharma and Global Health. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are IT Services, Pharma and Hospital Stocks?

IT services, pharma and hospital stocks are listed companies that provide IT, cloud and application services to global clients, develop and sell branded medicines for chronic and acute conditions, and run large multi speciality hospitals. Their earnings depend on client technology budgets, prescription demand and patient volumes.

IT Services, Pharma and Hospital Stocks at a Glance

On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing IT services, pharma and hospital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in IT services, pharma and hospital stocks can use the coming numbers to test whether growth is holding.

Why Do IT Services, Pharma and Hospital Stocks Have a Strong Roadmap in India?

IT services, pharma and hospital stocks have a strong roadmap in India because wider enterprise adoption of digital services, steady demand for branded medicines and rising need for quality hospital care keep widening the market for these companies.

• IT services. Large clients consolidate vendors for digital work.
• Specialty pharma. Doctors prescribe trusted branded medicines.
• Hospitals. Families seek quality specialist care.

Why Mphasis Features Among These IT Services, Pharma and Hospital Stocks

Among the IT services, pharma and hospital stocks on this list, Mphasis is a Bengaluru-based IT services company that provides applications, cloud, data and consulting services to clients in banking, insurance and technology, especially in the United States.

Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%.

In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5.

Roadmap: The company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.

What to watch: Monitor deal wins and client spending trends in banking and financial services.

Why Ajanta Pharma Features Among These IT Services, Pharma and Hospital Stocks

Among the software, branded medicine and care network shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.

Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.

Why Global Health Features Among These IT Services, Pharma and Hospital Stocks

Among the three companies on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.

The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.

Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore.

Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.

Mphasis vs Ajanta Pharma vs Global Health on Key Financials

The table below sets the three IT services, pharma and hospital stocks side by side on revenue, profit and margin, using reported figures.

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Mphasis has the largest FY26 revenue at Rs 16,206 crore, and Global Health shows the fastest revenue growth with a 19.6% compound annual rate. A useful habit with IT services, pharma and hospital stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several digital services firm, branded drug maker and hospital chain stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in IT Services, Pharma and Hospital Stocks

Every theme carries risks that deserve a check before any decision. For these IT services, pharma and hospital stocks, the main points are: Long-term software, branded medicine and care network shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Client spending. Technology budgets can vary with global conditions.
• Pricing pressure. Generic prices can change by market.
• Capacity ramp up. New hospitals take time to fill beds and reach full returns.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter IT services, pharma and hospital stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on IT Services, Pharma and Hospital Stocks

IT services, pharma and hospital stocks reward patient research into demand, execution and financial strength. Mphasis, Ajanta Pharma and Global Health each have a clear plan to grow. Based on the 11 November 2026 close, Mphasis trades at Rs 2,390, Ajanta Pharma at Rs 3,319.6 and Global Health at Rs 1,429. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these IT services, pharma and hospital stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track IT services, pharma and hospital stocks, set price alerts and get research-backed stock ideas.

What are IT services, pharma and hospital stocks?

Ans. IT services, pharma and hospital stocks are listed companies that provide IT, cloud and application services to global clients, develop and sell branded medicines for chronic and acute conditions, and run large multi speciality hospitals. Their earnings depend on client technology budgets, prescription demand and patient volumes. This list looks at three of them, Mphasis, Ajanta Pharma and Global Health, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which IT services, pharma and hospital stocks are covered in this list?

Ans. This list covers Mphasis, Ajanta Pharma and Global Health. Based on the 11 November 2026 close, Mphasis traded at Rs 2,390, Ajanta Pharma at Rs 3,319.6 and Global Health at Rs 1,429. Their return on equity ranges from 14.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.6%.

Why do IT services, pharma and hospital stocks have a strong future roadmap in India?

Ans. IT services, pharma and hospital stocks have a strong roadmap in India because wider enterprise adoption of digital services, steady demand for branded medicines and rising need for quality hospital care keep widening the market for these companies. The main drivers are as follows. IT services. Large clients consolidate vendors for digital work. Specialty pharma. Doctors prescribe trusted branded medicines. Hospitals. Families seek quality specialist care. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Mphasis performed financially?

Ans. Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Global Health performed financially?

Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What risks should investors check before buying IT services, pharma and hospital stocks?

Ans. Investors should check a few risks before buying IT services, pharma and hospital stocks. Client spending. Technology budgets can vary with global conditions. Pricing pressure. Generic prices can change by market. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of IT services, pharma and hospital stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.